Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 218

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 3
Chunk 218
---
936 2,783 Accounts payable2,945 3,688 Current portion of contingent consideration liabilities2,589 1,952 Salaries, wages and commissions1,986 1,802 Royalty and license arrangements527 360 Other6,658 6,438 Accounts payable and accrued liabilities$31,945 $30,650 Other Long-Term Liabilitiesas of December 31 (in millions)20242023Contingent consideration liabilities$19,077 $17,938 Liabilities for unrecognized tax benefits5,049 6,681 Income taxes payable1,261 2,182 Pension and other post-employment benefits1,234 1,538 Other3,508 3,988 Other long-term liabilities$30,129 $32,327 

2024 Form 10-K   |  62

Note 4 Earnings Per Share

AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method:Years ended December 31,(in millions, except per share data)202420232022Basic EPSNet earnings attributable to AbbVie Inc.$4,278 $4,863 $11,836 Earnings allocated to participating securities40 43 54 Earnings available to common shareholders$4,238 $4,820 $11,782 Weighted average basic shares of common stock outstanding1,769 1,768 1,771 Basic earnings per share attributable to AbbVie Inc.$2.40 $2.73 $6.65 Diluted EPSNet earnings attributable to AbbVie Inc.$4,278 $4,863 $11,836 Earnings allocated to participating securities40 43 54 Earnings available to common shareholders$4,238 $4,820 $11,782 Weighted average shares of common stock outstanding1,769 1,768 1,771 Effect of dilutive securities4 5 7 Weighted average diluted shares of common stock outstanding1,773 1,773 1,778 Dil